GlassScriptPhysician profile
Berent J Krumm
NPI 1801866769
$4,125.01
in general payments reported to CMS, 2019-2025
37 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $240 · 2021: $834 · 2022: $825 · 2023: $764 · 2024: $360 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,416 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,416.26 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $902.60 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $661.00 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $333.18 | 2019-2023 | Otezla, Repatha, Prolia |
| Pfizer INC. | $331.88 | 2019-2025 | |
| Abbott Laboratories | $205.80 | 2019-2024 | Freestyle Libre 3, Freestyle Insulinx |
| Lilly USA, LLC | $181.15 | 2021-2025 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.66 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $126.69 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Novo Nordisk INC | $120.17 | 2019-2023 | Wegovy |
| Allergan, INC. | $111.80 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $109.74 | 2019-2021 | |
| Glaxosmithkline, LLC. | $84.76 | 2022-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $82.35 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.66 | 2019-2021 | |
| Astellas Pharma US INC | $66.66 | 2019-2025 | Veozah |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Berent Krumm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.